Novo Nordisk and Regeneron Pharmaceuticals have been struggling this year, significantly underperforming the market. Novo Nordisk’s shares are down 18%, while Regeneron’s shares have dropped by 19%. Despite these challenges, both companies have strong potential for long-term growth. Novo Nordisk has a robust pipeline and strong financial results, while Regeneron has newer products gaining market share and a commitment to returning capital to shareholders. Investors looking for opportunities in the healthcare sector may find value in these companies, as they could see superior returns over time.

Read more at Nasdaq: 2 Healthcare Stocks That Are Losing to the S&P 500 This Year